Psyched Wellness (CSE:PSYC, OTCQB:PSYCF) Ltd CEO Jeff Stevens tells Proactive it has revealed key results from a 90-day oral toxicity preclinical study on its proprietary extract of the Amanita Muscaria mushroom (AME-1), with its contract research organization partner.
The Toronto-based company noted that the study was the third set of a group of thorough assessments on AME-1 conducted to determine the systemic toxicity potential of the Amanita Muscaria extract when administered once daily for 90 consecutive days, and summarizes the NOAEL (No Observed Adverse Event Level).